mCRPC VL

FDA Approves First PARP Inhibitor Rucaparib for Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Charles Ryan

Details
Alicia Morgans and Charles Ryan highlight the breaking news that the Food and Drug Administration (FDA) approved the first PARP Inhibitor for men with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA mutation. Rubraca® (rucaparib) tablets for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-res...

Outcomes from The PROCEED Registry: Survival of African-American and Caucasian Men After Sipuleucel-T Immunotherapy - Oliver Sartor

Details
The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED) (NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Oliver Sartor, the primary author joins Alicia Morgans to provide an update on the PROCEED registry aiming to understand outcomes for Afr...

Optimal Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Evan Yu

Details
In an area where we have multiple options for treatment and we continue to have more data that helps to guide us, Evan Yu joins Alicia Morgans to speak about systemic treatment sequencing in the metastatic castration-resistant prostate cancer (mCRPC) setting and his approach to moving a patient through the different phases of their treatment. Biographies: Evan Yu, MD, Medical oncologist, treats pr...

The ORIOLE Trial Results Discussed: Outcomes of Observation vs SABR for Oligometastatic Prostate Cancer - Phuoc T. Tran

Details
The ORIOLE Phase 2 Randomized Clinical Trial set out to answer the question, "how effectively does stereotactic ablative radiotherapy prevent progression of disease compared with observation in men with recurrent hormone-sensitive prostate cancer with 1 to 3 metastases?" Dr Tran joins Alicia Morgans and discusses this phase 2 randomized clinical trial of 54 men, where the progression of disease at...

Optimal Steroid Use with Abiraterone - Gerhardt (Gert) Attard

Details
Gerhardt Attard joins Charles Ryan to discuss the optimal steroid and dose to be given with abiraterone for the management of castration-resistant prostate cancer (CRPC). The two review the risks and benefits of either the standard dose of 5mg prednisone BID compared to a lower steroid dose of 5mg daily. Dr. Attard also shares his perspective on using dexamethasone, which has also shown to have an...

Radiation Oncology Studies: Changing the Course of Disease for Men with Metastatic Prostate Cancer - Phuoc Tran

Details
Phuoc Tran, Johns Hopkins University, provides an overview of several ongoing clinical trials for prostate cancer. SALV-ENZA is a Phase II randomized placebo-controlled trial of salvage radiation, which then randomizes to either to placebo or the oral next-generation antiandrogen drug known as enzalutamide. Dr. Tran also reviews the ORIOLE and RAVENS clinical trials which examine metastasis-direct...

Bone Health Agents in Patients with Castrate-Resistant Prostate Cancer - Bertrand Tombal

Details
Neal Shore and Bertrand Tombal discuss the importance of bone health agents, particularly in patients receiving castrate-resistant prostate cancer agents. Highlights of their conversation include the use of antiresorptive therapy to reduce the risk of skeletal-related events in men with bone mCRPC and decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial. Bi...

Immunotherapy and Personalized Medicine in Prostate Cancer - Akash Patnaik

Details
Akash Patnaik, an Assistant Professor of Medicine at the University of Chicago joins Alicia Morgans to speak about his work and expertise with immunotherapy in prostate cancer. Dr. Patnaik and Dr. Morgans discuss the work that he is doing in the lab to better understand why some patients have exceptional responses to combining two different immunotherapies targeting CTLA-4 and PD-1 in prostate can...

Cabazitaxel is a New Standard of Care for Third Line Metastatic Prostate Cancer - Bertrand Tombal

Details
Bertrand Tombal presents the recently published results from the CARD trial: "CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent". Enzalutamide in Metastatic Prostate Cancer (mCRPC) is highly heterogeneous with the coe...

Personalized Medicine in Prostate Cancer - Arpit Rao

Details
Arpit Rao joins Alicia Morgans to discuss new data on PARP inhibitors in prostate cancer. Dr. Rao shares his thoughts about the future of PARP, where things stand with PARP inhibitors currently, highlighting the PROfound study, TRITON2, and last year's TOPARP-B in advanced castration-resistant prostate cancer and what he thinks in terms of personalized medicine for this population. Biographies: Ar...
email news signup